Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company?s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cance
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-42.95%||ROE||-46.37%||ROI||-45.3%|
|Current Ratio||17.69||Quick Ratio||Long Term Debt/Equity||0.01||Debt Ratio||0.06|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||290 K||Cash From Investing Activities||16.76 M||Cash From Operating Activities||-34.5 M||Gross Profit||3.02 M|
|Net Profit||-39.07 M||Operating Profit||-39.37 M||Total Assets||253.02 M||Total Current Assets||223.26 M|
|Total Current Liabilities||18.73 M||Total Debt||4.83 M||Total Liabilities||28.18 M||Total Revenue||8.12 M|
|High 52 week||92.04||Low 52 week||37.84||Last close||91.76||Last change||-0.3%|
|RSI||55.98||Average true range||3.8||Beta||0.77||Volume||1.89 M|
|Simple moving average 20 days||4.46%||Simple moving average 50 days||19.12%||Simple moving average 200 days||34.27%|
|Performance Week||3.63%||Performance Month||16.48%||Performance Quart||41.76%||Performance Half||40.48%|
|Performance Year||103.96%||Performance Year-to-date||45.42%||Volatility daily||2.83%||Volatility weekly||6.33%|
|Volatility monthly||12.97%||Volatility yearly||44.92%||Relative Volume||250.33%||Average Volume||1.7 M|
|New High||New Low|
2019-04-16 14:34:40 | Did Hedge Funds Drop The Ball On EXACT Sciences Corporation EXAS ?
2019-04-12 11:26:01 | Goldman Adds EXACT Sciences To Americas Conviction List
2019-04-09 10:48:47 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-04-08 06:00:00 | Exact Sciences schedules first-quarter 2019 earnings call
2019-04-04 16:24:49 | Exact Sciences CEO on turning company around, stock soared 140% over the past year
2019-04-01 05:00:00 | Stocks That Would Have Made You Rich Today
2019-03-27 15:30:00 | Why Exact Sciences Stock Sank Today
2019-03-27 13:13:26 | 8 Genomic Testing Stocks That Can Ease the Sting of Theranos
2019-03-26 08:26:31 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-03-25 07:14:11 | Should You Invest in the Invesco DWA Healthcare Momentum ETF PTH?
2019-03-20 15:25:07 | NASH, Allergies and Beauty Stocks: Invest or Not?
2019-03-19 08:00:00 | Kathleen Sebelius Appointed to Exact Sciences Board
2019-03-17 11:33:00 | Better Buy: Exact Sciences vs. Illumina
2019-03-12 15:22:25 | 5 Active Mutual Funds Worth Their Expenses
2019-03-12 07:16:00 | Why Guardant Health Is the Best Healthcare Stock You've Never Heard Of
2019-03-10 08:12:00 | The 10 Top Stocks of the 10-Year Bull Market
2019-03-08 13:35:00 | Exact Sciences Looks Vulnerable: Protect Longs
2019-03-05 16:01:00 | Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027
2019-03-04 07:00:00 | Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst Ratings
2019-03-01 06:00:00 | Exact Sciences to participate in March investor conferences
2019-02-27 06:00:00 | Cologuard Helps Screen Two Million People for Colorectal Cancer
2019-02-26 12:14:39 | Exact Sciences A 'Must-Own' Growth Stock, Goldman Sachs Says In Upgrade
2019-02-24 09:00:00 | Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More.
2019-02-22 15:42:05 | Edited Transcript of EXAS earnings conference call or presentation 21-Feb-19 10:00pm GMT
2019-02-22 00:49:18 | EXACT Sciences Corporation EXAS Q4 2018 Earnings Conference Call Transcript
2019-02-21 18:45:11 | Exact Sciences EXAS Reports Q4 Loss, Misses Revenue Estimates
2019-02-21 17:56:35 | Exact Sciences: 4Q Earnings Snapshot
2019-02-21 17:34:28 | Exact Sciences completes 934,000 Cologuard tests in 2018; annual revenue up 71%
2019-02-21 09:28:02 | Options Traders Expect Huge Moves in Exact Sciences EXAS Stock
2019-02-20 16:06:00 | Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors
2019-02-19 18:18:11 | This Week's Hottest Earnings Charts
2019-02-17 09:18:00 | Could Exact Sciences Be a Millionaire-Maker Stock?
2019-02-13 07:24:12 | Should You Invest in the Invesco DWA Healthcare Momentum ETF PTH?
2019-02-10 09:00:00 | The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment
2019-02-08 08:06:46 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-02-07 08:07:00 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-02-05 08:06:46 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-02-04 21:47:00 | Here's Why Exact Sciences Soared 42.8% in January
2019-02-04 08:06:40 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-02-04 06:00:00 | Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
2019-01-30 08:05:58 | See what the IHS Markit Score report has to say about Exact Sciences Corp.
2019-01-29 09:03:00 | 4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test